Concepedia

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

Uwe Rix, Lily L. Remsing Rix, Andrew S. Terker, Nora V. Fernbach, Oliver Hantschel, Melanie Planyavsky, Florian P. Breitwieser, Harald Herrmann, Jacques Colinge, Keiryn L. Bennett,

Leukemia · 2009 · 76 citations · 27 references

DOIFull text

Open access

Concepts

References

27

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

, , +15

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

Marcus Bantscheff, Dirk Eberhard, Yann Abraham et al. · Nature Biotechnology · 2007 · 1K citations

, , +14

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

Nicholas J. Donato, Ji Yuan Wu, Jonathan Stapley et al. · Blood · 2002 · 663 citations · Full text

, , +11

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger et al. · Blood · 2007 · 663 citations · Full text

, , +17

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Oliver Hantschel, Uwe Rix, Uwe Schmidt et al. · Proceedings of the National Academy of Sciences · 2007 · 282 citations · Full text

, , +16